Jason is the Director for Market Access and Government Affairs in the Asia Pacific team at Cochlear. In this role he drives market access and government affairs strategies that achieve growth in implantable hearing solutions across the Asia-Pacific (APAC) region.
He has extensive public policy experience working in and with governments in Australia at both the State and Commonwealth level, as well as with governments across Asia Pacific.
Previously, Jason was Vice President for Government and Stakeholder Relations (APAC) for Canopy Growth Corporation where he built market access pathways for a range of Canopy’s products, including its therapeutic and medical device solutions across the Asia Pacific, and before that he was Chief of Staff to a Minister for Trade and Investment, Innovation and Digital Economy. Jason also served as a diplomat at the Australian Embassy in Japan.
Helen Oh joined Austrade in October 2020. She commenced her posting in the Australian Embassy in Seoul as Trade and Investment Commissioner and Counsellor (Commercial) in January 2021.
Prior to joining Austrade, Helen led the NSW State Government's market development and international engagement program for Korea and Japan. Helen was the onshore manager responsible for developing and maintaining $1 billion investment pipeline and key accounts portfolio in Australia. Her clients included Korean and Japanese corporates such as Samsung, Hyundai, POSCO, LG, Hitachi, Sumitomo Mitsui Financial Group, Mitsubishi Heavy Industries and Softbank Group.
Helen was named Asialink’s 40 Under 40 Most Influential Asian-Australian Leaders list in 2020. She is an active member of the Future Leaders Program facilitated by the Australia-Korea Business Council and the Australia-Japan Business Co-operation Committee. She represented Australia in amateur and professional golf from 2000 to 2010.
Rowan Petz is the Executive Director at the Australian Chamber of Commerce in Korea. Rowan brings a wealth of diverse experience and knowledge into his role having initially studied as a fraud investigator before moving into the currency management sector for six years.
Rowan’s passion for international trade and politics led him to a degree in International Relations from La Trobe University, Melbourne. Having received the Endeavour Australia Cheung Kong and the Victorian Government’s Hamer scholarship awards, Rowan was granted the opportunity to study International Relations and Korean language at Yonsei University in Seoul, South Korea.
With a strong passion for wanting to further strengthen the Australian-Korean relationship, Rowan commenced work at Chamber in 2016.
Rob Scott is the Managing Director of Australia and British Asia
Technology Incubators and market entry advisory firm China
BlueSky Partners.
Rob is an expert in healthcare technology commercialization,
market entry and business planning. Rob leverages 20 years’
experience (over 13 in China) in financial advisory and delivering
international business management, venture capital raising and
other transaction services for a range of clients both in Australia
and internationally where he has personally helped dozens of
Western startups, scaleups and SMEs succeed in challenging
Asian markets like China.
He has held senior executive roles in these areas with Big 4
accounting firm Ernst & Young for over 6 years and was the State
Leader of Ernst & Young’s China Business Group for his State of
Queensland. Rob was responsible helping several biotech and
medical technology capital raisings deals during this time, such
as the Panbio acquisitions by US multinational Inverness.
Rob resides in Shanghai and is a former Member of the
Australian Institute of Company Directors and former Executive
Director of the Queensland Chapter of the Australia China
Business Council.
Ruslan is a medtech/digital health specialist at Intralink – an international business development consultancy with a deep specialism in East Asia.
At Intralink, he mainly focuses on the life sciences and med-tech sectors and has helped dozens of clients in digital healthcare, genomics, precision medicine as well as advanced medical technologies to enter the Korean market. Specifically, he has brought several companies such as Oxford Nanopore Technologies, Syapse, Mission Bio and Random42 to the Korean market and recently licensed Molecular Health’s precision medicine platform to two of the top Korean hospitals and a clinical lab.
He has also been invited by the UK’s Department for International Trade to present on South Korean digital health opportunities in London, Manchester, and Cardiff and provides an annual webinar on the Korean life science opportunities for the global bank, Santander, and Washington State Department of Commerce.